Radioligand Therapies
Accelerate Radioligand Therapy Discovery with Integrated Biology Solutions
Radioligand therapies (RLTs) are transforming precision medicine by delivering targeted radiation directly to diseased tissues while minimizing systemic exposure. Successful development requires more than identifying a targeting ligand—it demands an integrated understanding of target biology, receptor expression, pharmacology, biodistribution, and safety throughout discovery and preclinical development.
WuXi Biology and Testing provides comprehensive discovery biology services that support radioligand therapy programs from target validation through candidate selection. By combining in vitro biology, in vivo pharmacology, imaging capabilities, DMPK, bioanalysis, and safety assessment, we help developers generate the critical data needed to confidently advance promising radioligand candidates.
Coordinating Across Disciplines
Integrated Expertise for Complex Radioligand Programs
Radioligand therapies require coordination across multiple scientific disciplines. From selecting the optimal molecular target to evaluating tumor uptake, receptor occupancy, pharmacokinetics, efficacy, and safety, every stage influences clinical success. We bring together multidisciplinary expertise to streamline radioligand therapy development through a single integrated workflow.
Addressing the Challenges of Radioligand Therapy Development
Challenges
Target Identification & Validation
- Selecting highly expressed disease targets
- Demonstrating target specificity
- Understanding receptor biology
- Identifying translational biomarkers
Solutions
Target Identification & Validation
- Target expression profiling
- Biomarker discovery
- Tissue characterization
- Functional biology assays
- Target validation strategies
Challenges
Ligand Screening
- Identifying high-affinity ligands
- Optimizing receptor binding
- Evaluating internalization
- Reducing off-target interactions
Solutions
Ligand Screening
- Receptor binding assays
- Cell-based screening
- Internalization assays
- Functional potency testing
- Candidate ranking
Challenges
Mechanism of Action
- Confirming biological activity
- Measuring target engagement
- Understanding receptor occupancy
- Predicting clinical response
Solutions
Mechanism of Action
- Cell signaling assays
- Flow cytometry
- Imaging assays
- Scintillation counting
- Gamma counting
- Biomarker evaluation
- Mechanistic studies
Challenges
Efficacy Evaluation
- Demonstrating tumor targeting
- Measuring biodistribution
- Optimizing dosing
- Evaluating therapeutic response
Solutions
Efficacy Evaluation
- Xenograft models
- Syngeneic models
- Biodistribution studies
- PK/PD assessment
- Imaging-based efficacy studies
Challenges
DMPK & Bioanalysis
- Characterizing exposure
- Understanding tissue distribution
- Measuring biomarkers
- Supporting regulatory submissions
Solutions
DMPK & Bioanalysis
- Bioanalytical method development
- PK studies
- Biomarker analysis
- Quantitative imaging support
- Integrated data interpretation
Challenges
Safety Assessment
- Characterizing toxicity
- Assessing off-target effects
- Designing regulatory studies
- Supporting IND submission
Solutions
Safety Assessment
- Dose range finding
- GLP toxicology
- Safety pharmacology
- Histopathology
- Regulatory support
Our Capabilities
- Target biology and biomarker evaluation
- Ligand screening and receptor binding assays
- Cell-based functional assays
- Internalization studies
- In vivo efficacy models
- Biodistribution evaluation
- Molecular imaging support
- DMPK and PK/PD studies
- Bioanalytical method development
- IND-enabling safety assessment
Discovery Biology Designed for Radioligand Therapies
Developing effective radioligand therapies begins with understanding disease biology. Our scientists work closely with sponsors to evaluate target expression, characterize receptor biology, and identify biomarkers that support candidate selection.
Integrated biology studies help establish confidence that selected targets demonstrate appropriate expression profiles, specificity, and translational potential before advancing into in vivo studies.
Evaluate Target Engagement and Therapeutic Activity
Radioligand therapies require rigorous in vitro characterization to confirm that a candidate ligand not only binds its target receptor but also internalizes into cells and triggers the desired biological response. WuXi Biology and Testing offers an integrated suite of cell-based assays to systematically evaluate every step of this mechanism of action. The foundational step focuses on target engagement, confirming that the radioligand successfully reaches and enters target cells to ensure effective payload delivery. Building on this, therapeutic activity assessments validate that target binding translates into measurable anti-tumor effects by evaluating target-dependent cell killing and the underlying mechanism of cytotoxicity. Ultimately, this end-to-end profiling generates the critical data needed to support informed lead candidate selection and reduce downstream development risks.
Core Capabilities:
- Receptor binding assays (Affinity, specificity, competitive binding)
- Internalization studies (Uptake kinetics, surface vs. internalized fraction)
- Cell viability assays (Cytotoxicity, EC50, selectivity index)
- Functional potency assays (Dose-response, biological activity ranking)
- Flow cytometry (Receptor expression, apoptosis, cell cycle analysis)
- High-content imaging (Subcellular localization, multiplexed phenotypic endpoints)
- Biomarker analysis (DNA damage markers, signaling pathway validation)
Integrated Preclinical Development Support
Following candidate selection, WuXi Biology and Testing seamlessly integrates pharmacology, DMPK, bioanalysis, and safety assessment services to accelerate progression toward IND.
Through a coordinated scientific team and unified project management approach, sponsors benefit from streamlined study execution, consistent data interpretation, and reduced program complexity. Integrated services include:
- Pharmacology
- Biodistribution studies
- PK/PD evaluation
- Bioanalysis
- Biomarker testing
- Safety Assessment
- Regulatory support
Related Services
Radioligand therapy development depends on expertise across multiple scientific disciplines. Explore the integrated services that support every stage of your program.
Discovery Biology
Identify, validate, and characterize therapeutic targets while advancing lead radioligand candidates through comprehensive biology studies.
Learn More
DMPK
Understand exposure, biodistribution, pharmacokinetics, and tissue distribution to optimize radioligand performance.
Learn More
Bioanalysis
Develop sensitive analytical methods to quantify biomarkers, therapeutic exposure, and support translational decision making.
Learn More
Safety Assessment
Generate the safety data needed to confidently advance radioligand therapies into IND-enabling studies and clinical development.
Learn More
You May Also Be Interested In
Discuss Your Program with Us
Share your development goals and key challenges with our experts to define the right path forward.
Frequently Asked Questions
Radioligand therapies combine a targeting molecule with a radioactive isotope to selectively deliver radiation to diseased cells while minimizing exposure to healthy tissues.
Although oncology remains the primary application, radioligand therapies are also being investigated for cardiovascular, neurological, inflammatory, and other diseases characterized by specific molecular targets.
Target validation confirms that the selected receptor or antigen is highly expressed on diseased tissues while exhibiting limited expression in healthy tissues, improving the potential for selective targeting and therapeutic efficacy.
In vitro studies supporting radioligand therapy (RLT) discovery encompass a comprehensive testing cascade that evaluates both the biological targeting and radiochemical properties of a candidate. The process begins with target validation and ligand binding assays to optimize receptor affinity and specificity, alongside radiochemistry studies to ensure the stability of the radiometal-chelator complex. Crucially, cellular internalization and retention assays verify that the radioligand effectively enters and remains within target cells to deliver the radiation payload. Finally, in vitro efficacy and radiobiology evaluations - such as clonogenic survival, DNA damage quantification (e.g., γ-H2AX), and selectivity profiling - demonstrate target-dependent cell killing and validate the mechanism of cytotoxicity. Together, this integrated in vitro data package acts as a critical funnel to de-risk and select the most promising lead radioligand candidates before advancing to complex in vivo studies.
Preclinical studies evaluate biodistribution, pharmacokinetics, tumor uptake, therapeutic efficacy, imaging characteristics, and dose-response relationships using disease-relevant animal models.
DMPK studies characterize absorption, distribution, metabolism, pharmacokinetics, tissue exposure, and pharmacodynamic relationships that inform candidate optimization and clinical translation.
Bioanalysis provides the quantitative methods needed to measure therapeutic concentrations, biomarkers, metabolites, and other critical endpoints throughout discovery and development.
Yes. WuXi Biology and Testing integrates Discovery Biology, DMPK, Bioanalysis, and Safety Assessment services to support programs from early discovery through IND-enabling studies.